{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T03:32:43Z","timestamp":1762918363380,"version":"3.37.3"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,2,15]],"date-time":"2023-02-15T00:00:00Z","timestamp":1676419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,15]],"date-time":"2023-02-15T00:00:00Z","timestamp":1676419200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000265","name":"RCUK | Medical Research Council","doi-asserted-by":"publisher","award":["MR\/S037160\/1","MR\/S037160\/1","MR\/S037160\/1","MR\/S037160\/1","MR\/S037160\/1","MR\/S037160\/1","MR\/S037160\/1","MR\/S037160\/1","MR\/S037160\/1","MR\/S037160\/1","MR\/S037160\/1","MR\/S037160\/1","MR\/S037160\/1","MR\/S037160\/1","MR\/S037160\/1","MR\/S037160\/1"],"award-info":[{"award-number":["MR\/S037160\/1","MR\/S037160\/1","MR\/S037160\/1","MR\/S037160\/1","MR\/S037160\/1","MR\/S037160\/1","MR\/S037160\/1","MR\/S037160\/1","MR\/S037160\/1","MR\/S037160\/1","MR\/S037160\/1","MR\/S037160\/1","MR\/S037160\/1","MR\/S037160\/1","MR\/S037160\/1","MR\/S037160\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000870","name":"Pirbright Institute","doi-asserted-by":"publisher","award":["BBS\/E\/I\/00007031","BBS\/E\/I\/00007037","BBS\/E\/I\/00007039","BBS\/E\/I\/00007031","BBS\/E\/I\/00007037","BBS\/E\/I\/00007039","BBS\/E\/I\/00007031","BBS\/E\/I\/00007037","BBS\/E\/I\/00007039","BBS\/E\/I\/00007031","BBS\/E\/I\/00007037","BBS\/E\/I\/00007039","BBS\/E\/I\/00007031","BBS\/E\/I\/00007037","BBS\/E\/I\/00007039","BBS\/E\/I\/00007031","BBS\/E\/I\/00007037","BBS\/E\/I\/00007039","BBS\/E\/I\/00007031","BBS\/E\/I\/00007037","BBS\/E\/I\/00007039","BBS\/E\/I\/00007031","BBS\/E\/I\/00007037","BBS\/E\/I\/00007039","BBS\/E\/I\/00007031","BBS\/E\/I\/00007037","BBS\/E\/I\/00007039"],"award-info":[{"award-number":["BBS\/E\/I\/00007031","BBS\/E\/I\/00007037","BBS\/E\/I\/00007039","BBS\/E\/I\/00007031","BBS\/E\/I\/00007037","BBS\/E\/I\/00007039","BBS\/E\/I\/00007031","BBS\/E\/I\/00007037","BBS\/E\/I\/00007039","BBS\/E\/I\/00007031","BBS\/E\/I\/00007037","BBS\/E\/I\/00007039","BBS\/E\/I\/00007031","BBS\/E\/I\/00007037","BBS\/E\/I\/00007039","BBS\/E\/I\/00007031","BBS\/E\/I\/00007037","BBS\/E\/I\/00007039","BBS\/E\/I\/00007031","BBS\/E\/I\/00007037","BBS\/E\/I\/00007039","BBS\/E\/I\/00007031","BBS\/E\/I\/00007037","BBS\/E\/I\/00007039","BBS\/E\/I\/00007031","BBS\/E\/I\/00007037","BBS\/E\/I\/00007039"]}],"id":[{"id":"10.13039\/501100000870","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>There is an urgent need for influenza vaccines providing broader protection that may decrease the need for annual immunization of the human population. We investigated the efficacy of heterologous prime boost immunization with chimpanzee adenovirus (ChAdOx2) and modified vaccinia Ankara (MVA) vectored vaccines, expressing conserved influenza virus nucleoprotein (NP), matrix protein 1 (M1) and neuraminidase (NA) in H1N1pdm09 pre-exposed pigs. We compared the efficacy of intra-nasal, aerosol and intra-muscular vaccine delivery against H3N2 influenza challenge. Aerosol prime boost immunization induced strong local lung T cell and antibody responses and abrogated viral shedding and lung pathology following H3N2 challenge. In contrast, intramuscular immunization induced powerful systemic responses and weak local lung responses but also abolished lung pathology and reduced viral shedding. These results provide valuable insights into the development of a broadly protective influenza vaccine in a highly relevant large animal model and will inform future vaccine and clinical trial design.<\/jats:p>","DOI":"10.1038\/s41541-023-00620-2","type":"journal-article","created":{"date-parts":[[2023,2,21]],"date-time":"2023-02-21T13:34:08Z","timestamp":1676986448000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Immunization with matrix-, nucleoprotein and neuraminidase protects against H3N2 influenza challenge in pH1N1 pre-exposed pigs"],"prefix":"10.1038","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2864-4962","authenticated-orcid":false,"given":"Eleni","family":"Vatzia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine","family":"Feest","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"McNee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanuja","family":"Manjegowda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B. Veronica","family":"Carr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Basudev","family":"Paudyal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiphany","family":"Chrun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuel A.","family":"Maze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy","family":"Mccarron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Morris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1233-4265","authenticated-orcid":false,"given":"Helen E.","family":"Everett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3164-1607","authenticated-orcid":false,"given":"Ronan","family":"MacLoughlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco J.","family":"Salguero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Lambe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6823-9750","authenticated-orcid":false,"given":"Sarah C.","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4869-5118","authenticated-orcid":false,"given":"Elma","family":"Tchilian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,2,15]]},"reference":[{"key":"620_CR1","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1586\/14760584.3.6.643","volume":"3","author":"R Belshe","year":"2004","unstructured":"Belshe, R., Lee, M.-S., Walker, R. E., Stoddard, J. & Mendelman, P. M. Safety, immunogenicity and efficacy of intranasal, live attenuated influenza vaccine. Expert Rev. Vaccines 3, 643\u2013654 (2004).","journal-title":"Expert Rev. Vaccines"},{"key":"620_CR2","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1093\/infdis\/jir436","volume":"204","author":"DF Hoft","year":"2011","unstructured":"Hoft, D. F. et al. Live and inactivated influenza vaccines induce similar humoral responses, but only live vaccines induce diverse T-cell responses in young children. J. Infect. Dis. 204, 845\u2013853 (2011).","journal-title":"J. Infect. Dis."},{"doi-asserted-by":"publisher","unstructured":"Jeyanathan, M. et al. Aerosol delivery, but not intramuscular injection, of adenovirus-vectored tuberculosis vaccine induces respiratory-mucosal immunity in humans. JCI Insight 7, https:\/\/doi.org\/10.1172\/jci.insight.155655 (2022).","key":"620_CR3","DOI":"10.1172\/jci.insight.155655"},{"key":"620_CR4","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1056\/NEJMoa1407417","volume":"372","author":"N Low","year":"2015","unstructured":"Low, N. et al. A randomized, controlled trial of an aerosolized vaccine against measles. N. Engl. J. Med. 372, 1519\u20131529 (2015).","journal-title":"N. Engl. J. Med."},{"key":"620_CR5","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S1473-3099(14)70845-X","volume":"14","author":"I Satti","year":"2014","unstructured":"Satti, I. et al. Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1, double-blind, randomised controlled trial. Lancet Infect. Dis. 14, 939\u2013946 (2014).","journal-title":"Lancet Infect. Dis."},{"doi-asserted-by":"publisher","unstructured":"van Doremalen, N. et al. Intranasal ChAdOx1 nCoV-19\/AZD1222 vaccination reduces viral shedding after SARS-CoV-2 D614G challenge in preclinical models. Sci. Transl. Med. 13, https:\/\/doi.org\/10.1126\/scitranslmed.abh0755 (2021).","key":"620_CR6","DOI":"10.1126\/scitranslmed.abh0755"},{"key":"620_CR7","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1016\/S1473-3099(21)00396-0","volume":"21","author":"S Wu","year":"2021","unstructured":"Wu, S. et al. Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial. Lancet Infect. Dis. 21, 1654\u20131664 (2021).","journal-title":"Lancet Infect. Dis."},{"key":"620_CR8","doi-asserted-by":"publisher","first-page":"e0190821","DOI":"10.1128\/mBio.01908-21","volume":"12","author":"JH Lara-Puente","year":"2021","unstructured":"Lara-Puente, J. H. et al. Safety and immunogenicity of a newcastle disease virus vector-based SARS-CoV-2 vaccine candidate, AVX\/COVID-12-HEXAPRO (Patria), in pigs. mBio 12, e0190821 (2021).","journal-title":"mBio"},{"key":"620_CR9","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/S2213-2600(22)00087-X","volume":"10","author":"J-X Li","year":"2022","unstructured":"Li, J.-X. et al. Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open-label, single-centre trial. Lancet Respir. Med. 10, 739\u2013748 (2022).","journal-title":"Lancet Respir. Med."},{"key":"620_CR10","doi-asserted-by":"publisher","first-page":"3634","DOI":"10.1016\/j.vaccine.2005.02.019","volume":"23","author":"D Nardelli-Haefliger","year":"2005","unstructured":"Nardelli-Haefliger, D. et al. Immune responses induced by lower airway mucosal immunisation with a human papillomavirus type 16 virus-like particle vaccine. Vaccine 23, 3634\u20133641 (2005).","journal-title":"Vaccine"},{"key":"620_CR11","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1586\/14760584.6.2.213","volume":"6","author":"D Lu","year":"2007","unstructured":"Lu, D. & Hickey, A. J. Pulmonary vaccine delivery. Expert Rev. Vaccines 6, 213\u2013226 (2007).","journal-title":"Expert Rev. Vaccines"},{"key":"620_CR12","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.vaccine.2016.12.008","volume":"35","author":"DL Bolton","year":"2017","unstructured":"Bolton, D. L., Song, K., Tomaras, G. D., Rao, S. & Roederer, M. Unique cellular and humoral immunogenicity profiles generated by aerosol, intranasal, or parenteral vaccination in rhesus macaques. Vaccine 35, 639\u2013646 (2017).","journal-title":"Vaccine"},{"key":"620_CR13","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1111\/imr.12900","volume":"296","author":"M Knight","year":"2020","unstructured":"Knight, M., Changrob, S., Li, L. & Wilson, P. C. Imprinting, immunodominance, and other impediments to generating broad influenza immunity. Immunol. Rev. 296, 191\u2013204 (2020).","journal-title":"Immunol. Rev."},{"doi-asserted-by":"publisher","unstructured":"Dugan, H. L. et al. Preexisting immunity shapes distinct antibody landscapes after influenza virus infection and vaccination in humans. Sci. Transl. Med. 12; https:\/\/doi.org\/10.1126\/scitranslmed.abd3601 (2020).","key":"620_CR14","DOI":"10.1126\/scitranslmed.abd3601"},{"key":"620_CR15","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/ni.3684","volume":"18","author":"R Nachbagauer","year":"2017","unstructured":"Nachbagauer, R. et al. Defining the antibody cross-reactome directed against the influenza virus surface glycoproteins. Nat. Immunol. 18, 464\u2013473 (2017).","journal-title":"Nat. Immunol."},{"key":"620_CR16","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1038\/nm.3350","volume":"19","author":"S Sridhar","year":"2013","unstructured":"Sridhar, S. et al. Cellular immune correlates of protection against symptomatic pandemic influenza. Nat. Med. 19, 1305\u20131312 (2013).","journal-title":"Nat. Med."},{"key":"620_CR17","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/nm.2612","volume":"18","author":"TM Wilkinson","year":"2012","unstructured":"Wilkinson, T. M. et al. Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans. Nat. Med. 18, 274\u2013280 (2012).","journal-title":"Nat. Med."},{"key":"620_CR18","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1164\/rccm.201411-1988OC","volume":"191","author":"AC Hayward","year":"2015","unstructured":"Hayward, A. C. et al. Natural T cell-mediated protection against seasonal and pandemic influenza. Results of the flu watch cohort study. Am. J. Respir. Crit. Care Med. 191, 1422\u20131431 (2015).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"620_CR19","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJM198307073090103","volume":"309","author":"AJ McMichael","year":"1983","unstructured":"McMichael, A. J., Gotch, F. M., Noble, G. R. & Beare, P. A. Cytotoxic T-cell immunity to influenza. N. Engl. J. Med. 309, 13\u201317 (1983).","journal-title":"N. Engl. J. Med."},{"key":"620_CR20","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1038\/mt.2013.284","volume":"22","author":"RD Antrobus","year":"2014","unstructured":"Antrobus, R. D. et al. Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved Influenza A antigens. Mol. Ther.: J. Am. Soc. Gene Ther. 22, 668\u2013674 (2014).","journal-title":"Mol. Ther.: J. Am. Soc. Gene Ther."},{"key":"620_CR21","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.ebiom.2018.02.011","volume":"29","author":"L Coughlan","year":"2018","unstructured":"Coughlan, L. et al. Heterologous two-dose vaccination with simian adenovirus and poxvirus vectors elicits long-lasting cellular immunity to influenza virus A in healthy adults. EBioMedicine 29, 146\u2013154 (2018).","journal-title":"EBioMedicine"},{"key":"620_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/srep01443","volume":"3","author":"T Lambe","year":"2013","unstructured":"Lambe, T. et al. Immunity against heterosubtypic influenza virus induced by adenovirus and MVA expressing nucleoprotein and matrix protein-1. Sci. Rep. 3, 1443 (2013).","journal-title":"Sci. Rep."},{"key":"620_CR23","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1093\/cid\/cis327","volume":"55","author":"PJ Lillie","year":"2012","unstructured":"Lillie, P. J. et al. Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP+M1, in humans. Clin. Infect. Dis.: Off. Publ. Infect. Dis. Soc. Am. 55, 19\u201325 (2012).","journal-title":"Clin. Infect. Dis.: Off. Publ. Infect. Dis. Soc. Am."},{"key":"620_CR24","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1093\/infdis\/jiz593","volume":"222","author":"S Puksuriwong","year":"2020","unstructured":"Puksuriwong, S. et al. Modified vaccinia ankara-vectored vaccine expressing nucleoprotein and matrix protein 1 (M1) activates mucosal M1-specific T-cell immunity and tissue-resident memory T cells in human nasopharynx-associated lymphoid tissue. J. Infect. Dis. 222, 807\u2013819 (2020).","journal-title":"J. Infect. Dis."},{"key":"620_CR25","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.coviro.2013.07.007","volume":"3","author":"F Krammer","year":"2013","unstructured":"Krammer, F. & Palese, P. Influenza virus hemagglutinin stalk-based antibodies and vaccines. Curr. Opin. Virol. 3, 521\u2013530 (2013).","journal-title":"Curr. Opin. Virol."},{"doi-asserted-by":"publisher","unstructured":"Krammer, F. et al. NAction! How can neuraminidase-based immunity contribute to better influenza virus vaccines? mBio 9; https:\/\/doi.org\/10.1128\/mBio.02332-17 (2018).","key":"620_CR26","DOI":"10.1128\/mBio.02332-17"},{"key":"620_CR27","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.chom.2019.11.006","volume":"26","author":"F Krammer","year":"2019","unstructured":"Krammer, F., Li, L. & Wilson, P. C. Emerging from the shadow of hemagglutinin: neuraminidase is an important target for influenza vaccination. Cell Host Microbe 26, 712\u2013713 (2019).","journal-title":"Cell Host Microbe"},{"key":"620_CR28","first-page":"301","volume":"386","author":"F Krammer","year":"2015","unstructured":"Krammer, F., Palese, P. & Steel, J. Advances in universal influenza virus vaccine design and antibody mediated therapies based on conserved regions of the hemagglutinin. Curr. Top. Microbiol. Immunol. 386, 301\u2013321 (2015).","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"620_CR29","doi-asserted-by":"publisher","first-page":"e0075921","DOI":"10.1128\/JVI.00759-21","volume":"95","author":"AL Skarlupka","year":"2021","unstructured":"Skarlupka, A. L., Bebin-Blackwell, A.-G., Sumner, S. F. & Ross, T. M. Universal influenza virus neuraminidase vaccine elicits protective immune responses against human seasonal and pre-pandemic strains. J. Virol. 95, e0075921 (2021).","journal-title":"J. Virol."},{"key":"620_CR30","doi-asserted-by":"publisher","first-page":"4068","DOI":"10.4049\/jimmunol.1800142","volume":"200","author":"B Holzer","year":"2018","unstructured":"Holzer, B. et al. Comparison of heterosubtypic protection in ferrets and pigs induced by a single-cycle influenza vaccine. J. Immunol. 200, 4068\u20134077 (2018).","journal-title":"J. Immunol."},{"key":"620_CR31","doi-asserted-by":"publisher","first-page":"5014","DOI":"10.4049\/jimmunol.1502632","volume":"196","author":"SB Morgan","year":"2016","unstructured":"Morgan, S. B. et al. Aerosol delivery of a candidate universal influenza vaccine reduces viral load in pigs challenged with pandemic H1N1 virus. J. Immunol. 196, 5014\u20135023 (2016).","journal-title":"J. Immunol."},{"key":"620_CR32","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1177\/0300985813513043","volume":"51","author":"BH Janke","year":"2014","unstructured":"Janke, B. H. Influenza A virus infections in swine: pathogenesis and diagnosis. Vet. Pathol. 51, 410\u2013426 (2014).","journal-title":"Vet. Pathol."},{"key":"620_CR33","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1093\/ilar\/ilv002","volume":"56","author":"DS Rajao","year":"2015","unstructured":"Rajao, D. S. & Vincent, A. L. Swine as a model for influenza A virus infection and immunity. ILAR J. 56, 44\u201352 (2015).","journal-title":"ILAR J."},{"key":"620_CR34","doi-asserted-by":"publisher","first-page":"763912","DOI":"10.3389\/fimmu.2021.763912","volume":"12","author":"E Vatzia","year":"2021","unstructured":"Vatzia, E. et al. Respiratory and intramuscular immunization with ChAdOx2-NPM1-NA induces distinct immune responses in H1N1pdm09 pre-exposed pigs. Front. Immunol. 12, 763912 (2021).","journal-title":"Front. Immunol."},{"key":"620_CR35","doi-asserted-by":"publisher","first-page":"594470","DOI":"10.3389\/fimmu.2020.594470","volume":"11","author":"V Martini","year":"2020","unstructured":"Martini, V. et al. Distribution of droplets and immune responses after aerosol and intra-nasal delivery of influenza virus to the respiratory tract of pigs. Front. Immunol. 11, 594470 (2020).","journal-title":"Front. Immunol."},{"key":"620_CR36","doi-asserted-by":"publisher","first-page":"652","DOI":"10.4049\/jimmunol.2001086","volume":"206","author":"V Martini","year":"2021","unstructured":"Martini, V. et al. Simultaneous aerosol and intramuscular immunization with influenza vaccine induces powerful protective local T cell and systemic antibody immune responses in pigs. J. Immunol. 206, 652\u2013663 (2021).","journal-title":"J. Immunol."},{"key":"620_CR37","first-page":"3273","volume":"118","author":"PC Doherty","year":"2008","unstructured":"Doherty, P. C. & Kelso, A. Toward a broadly protective influenza vaccine. J. Clin. Investig. 118, 3273\u20133275 (2008).","journal-title":"J. Clin. Investig."},{"doi-asserted-by":"publisher","unstructured":"Sun, W., Luo, T., Liu, W. & Li, J. Progress in the development of universal influenza vaccines. Viruses 12, https:\/\/doi.org\/10.3390\/v12091033 (2020).","key":"620_CR38","DOI":"10.3390\/v12091033"},{"doi-asserted-by":"publisher","unstructured":"Everett, H. E. et al. Vaccines that reduce viral shedding do not prevent transmission of H1N1 pandemic 2009 swine influenza A virus infection to unvaccinated pigs. J. Virol. 95; https:\/\/doi.org\/10.1128\/JVI.01787-20 (2021).","key":"620_CR39","DOI":"10.1128\/JVI.01787-20"},{"key":"620_CR40","doi-asserted-by":"publisher","first-page":"903755","DOI":"10.3389\/fimmu.2022.903755","volume":"13","author":"B Paudyal","year":"2022","unstructured":"Paudyal, B. et al. Fc-mediated functions of porcine IgG subclasses. Front. Immunol. 13, 903755 (2022).","journal-title":"Front. Immunol."},{"doi-asserted-by":"publisher","unstructured":"McMahon, M. et al. Mucosal immunity against neuraminidase prevents influenza B virus transmission in guinea pigs. mBio 10; https:\/\/doi.org\/10.1128\/mBio.00560-19 (2019).","key":"620_CR41","DOI":"10.1128\/mBio.00560-19"},{"key":"620_CR42","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1002\/jmv.10143","volume":"67","author":"Y Abed","year":"2002","unstructured":"Abed, Y., Hardy, I., Li, Y. & Boivin, G. Divergent evolution of hemagglutinin and neuraminidase genes in recent influenza A:H3N2 viruses isolated in Canada. J. Med. Virol. 67, 589\u2013595 (2002).","journal-title":"J. Med. Virol."},{"key":"620_CR43","doi-asserted-by":"publisher","first-page":"20748","DOI":"10.1073\/pnas.1113801108","volume":"108","author":"MR Sandbulte","year":"2011","unstructured":"Sandbulte, M. R. et al. Discordant antigenic drift of neuraminidase and hemagglutinin in H1N1 and H3N2 influenza viruses. Proc. Natl Acad. Sci. USA 108, 20748\u201320753 (2011).","journal-title":"Proc. Natl Acad. Sci. USA"},{"doi-asserted-by":"publisher","unstructured":"Rijal, P. et al. Broadly inhibiting antineuraminidase monoclonal antibodies induced by trivalent influenza vaccine and H7N9 infection in humans. J. Virol. 94; https:\/\/doi.org\/10.1128\/JVI.01182-19 (2020).","key":"620_CR44","DOI":"10.1128\/JVI.01182-19"},{"key":"620_CR45","doi-asserted-by":"publisher","first-page":"e0224121","DOI":"10.1128\/mBio.02241-21","volume":"12","author":"S Strohmeier","year":"2021","unstructured":"Strohmeier, S. et al. A novel recombinant influenza virus neuraminidase vaccine candidate stabilized by a measles virus phosphoprotein tetramerization domain provides robust protection from virus challenge in the mouse model. mBio 12, e0224121 (2021).","journal-title":"mBio"},{"doi-asserted-by":"publisher","unstructured":"Folegatti, P. M. et al. Safety and immunogenicity of a novel recombinant simian adenovirus ChAdOx2 as a vectored vaccine. Vaccines 7, https:\/\/doi.org\/10.3390\/vaccines7020040 (2019).","key":"620_CR46","DOI":"10.3390\/vaccines7020040"},{"key":"620_CR47","doi-asserted-by":"publisher","first-page":"649","DOI":"10.2217\/fvl-2016-0070","volume":"11","author":"SJ Morris","year":"2016","unstructured":"Morris, S. J., Sebastian, S., Spencer, A. J. & Gilbert, S. C. Simian adenoviruses as vaccine vectors. Future Virol. 11, 649\u2013659 (2016).","journal-title":"Future Virol."},{"key":"620_CR48","doi-asserted-by":"publisher","DOI":"10.1186\/s13567-016-0390-5","volume":"47","author":"JD Hemmink","year":"2016","unstructured":"Hemmink, J. D. et al. Distinct immune responses and virus shedding in pigs following aerosol, intra-nasal and contact infection with pandemic swine influenza A virus, A(H1N1)09. Vet. Res. 47, 103 (2016).","journal-title":"Vet. Res."},{"key":"620_CR49","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1177\/030098589503200606","volume":"32","author":"PG Halbur","year":"1995","unstructured":"Halbur, P. G. et al. Comparison of the pathogenicity of two US porcine reproductive and respiratory syndrome virus isolates with that of the Lelystad virus. Vet. Pathol. 32, 648\u2013660 (1995).","journal-title":"Vet. Pathol."},{"key":"620_CR50","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1177\/0300985812439724","volume":"49","author":"PC Gauger","year":"2012","unstructured":"Gauger, P. C. et al. Kinetics of lung lesion development and pro-inflammatory cytokine response in pigs with vaccine-associated enhanced respiratory disease induced by challenge with pandemic (2009) A\/H1N1 influenza virus. Vet. Pathol. 49, 900\u2013912 (2012).","journal-title":"Vet. Pathol."}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-023-00620-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-023-00620-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-023-00620-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,21]],"date-time":"2023-02-21T13:34:14Z","timestamp":1676986454000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-023-00620-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,15]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["620"],"URL":"https:\/\/doi.org\/10.1038\/s41541-023-00620-2","relation":{},"ISSN":["2059-0105"],"issn-type":[{"type":"electronic","value":"2059-0105"}],"subject":[],"published":{"date-parts":[[2023,2,15]]},"assertion":[{"value":"13 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare the following competing financial interests: S.C.G. is co-founder of Vaccitech and named as an inventor on a patent covering use of ChAdOx2-vectored vaccines. T.L. is a consultant to Vaccitech. RM is an employee of Aerogen Limited.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19"}}